CVKD Company Profile and Key Details

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD) closed at $1.75 USD, gaining $0.21 (13.64%) from the previous close of $1.54. The stock is currently mid-range between its 52-week high and low $1.46 and $14.64. With a market capitalization of about $6.24 million, Cadrenal Therapeutics, Inc. Common Stock is classified as a micro-cap and shows higher-than-market volatility (beta ~1.86). Key stats such as the average daily volume over the past year has been around 407.44 thousand shares, trading with heavier-than-usual volume. Headquartered in Ponte Vedra, FL, Cadrenal Therapeutics, Inc. Common Stock operates in the Healthcare sector and the Biotechnology industry. Led by CEO Quang X. Pham, the company employs approximately 5 people and listed since January 20, 2023. Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development.

Short-term trend indicators are bullishly aligned (SMA20 31.32%, SMA50 16.53%, SMA200 -25.56%). The stock’s 14-day RSI is 62.94 (firm momentum), while the ATR of 0.72 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -63.41% below its high and over 70.67% above its low. Average 10-day trading volume of 3.09 million shares is significantly above the 3-month average of 404.70 thousand, indicating heightened recent market interest.

Cadrenal Therapeutics, Inc. Common Stock trades at a P/E ratio of -0.36, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.26 suggesting the stock is closer to book value. The P/FCF stands at -0.62, also above market averages.

Cadrenal Therapeutics, Inc. Common Stock last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $2.01. This means the shares are trading below this model’s fair value.

Wall Street analysts project EPS growth of 35.34% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 1 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $13.00 to $13.00. The high target offers 642.86% upside. The low target suggests 642.86% downside. The mean target is $13.00. This offers 642.86% upside. Cadrenal Therapeutics, Inc. Common Stock earnings surprise history is a mixed track record. The quarter that ended August 13, 2026, missed forecasts by -19.72%. The prior quarter beat by -31.13%. Over the last six quarters, Apple has recorded several small beats. These include 27.44% in May 08, 2025.

Cadrenal Therapeutics, Inc. Common Stock has 3.57 million shares outstanding. The public float is 3.14 million shares, elevated short interest at 1.97% of float. This equals 61.10 thousand shares. The short ratio is 0.73 days. Institutional investors hold 3.56% of the float. Insiders own 13.73%. MURPHY JOHN RAYMOND holds 614.79 thousand shares, Pham Quang X has 98.59 thousand shares and Szot Matthew K has 0.00 shares. Over the past six months, insider transactions show net selling. They sold 97.50 thousand shares across 22 transactions.